K. Mary Swarnalatha, V.T.Iswariya, Banoth Akash, Sneha Bhandari, Ramavath Shirisha, T.Ramarao
{"title":"FORMULATION AND EVALUATION OF LOSARTAN POTASSIUM MATRIX TABLETS BY USING DIFFERENT POLYMERS","authors":"K. Mary Swarnalatha, V.T.Iswariya, Banoth Akash, Sneha Bhandari, Ramavath Shirisha, T.Ramarao","doi":"10.36713/epra17266","DOIUrl":null,"url":null,"abstract":"The study aims to create a sustained release matrix tablet for Losartan potassium, an angiotensin II receptor antagonist, to improve patient compliance and maintain therapeutic blood or tissue levels for extended periods. The research investigates the role of novel semi-synthetic polymers and natural polymers in comparison to well-known release retarding agents. Gastroretentive drug delivery systems (GRDDS) are unique technologies designed to improve drug bioavailability and absorption by avoiding the first-pass effect. Losartan potassium, an angiotensin II receptor antagonist, has a bioavailability of 32% and a low elimination half-life, making it suitable for oral controlled release. The study utilized natural and synthetic polymers in matrix tablet preparation, concentration, drug particles size, additives, and excipients to modify drug release. The powder mixtures were tested for pre-compression parameters and post-compression parameters, and in-vitro dissolution studies showed good dissolution profiles for drug release. Formulations with higher concentrations and polymers sustained drug release for 24 hours. FT-IR Spectroscopy confirmed drug compatibility with polymers and other excipients\nKEYWORDS: matrix tablets, Losartan Potassium, flow properties, pre compression parameters post compression parameters, In-vitro dissolution.","PeriodicalId":505883,"journal":{"name":"EPRA International Journal of Multidisciplinary Research (IJMR)","volume":" 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EPRA International Journal of Multidisciplinary Research (IJMR)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36713/epra17266","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The study aims to create a sustained release matrix tablet for Losartan potassium, an angiotensin II receptor antagonist, to improve patient compliance and maintain therapeutic blood or tissue levels for extended periods. The research investigates the role of novel semi-synthetic polymers and natural polymers in comparison to well-known release retarding agents. Gastroretentive drug delivery systems (GRDDS) are unique technologies designed to improve drug bioavailability and absorption by avoiding the first-pass effect. Losartan potassium, an angiotensin II receptor antagonist, has a bioavailability of 32% and a low elimination half-life, making it suitable for oral controlled release. The study utilized natural and synthetic polymers in matrix tablet preparation, concentration, drug particles size, additives, and excipients to modify drug release. The powder mixtures were tested for pre-compression parameters and post-compression parameters, and in-vitro dissolution studies showed good dissolution profiles for drug release. Formulations with higher concentrations and polymers sustained drug release for 24 hours. FT-IR Spectroscopy confirmed drug compatibility with polymers and other excipients
KEYWORDS: matrix tablets, Losartan Potassium, flow properties, pre compression parameters post compression parameters, In-vitro dissolution.
该研究旨在为血管紧张素 II 受体拮抗剂洛沙坦钾制造一种缓释基质片剂,以提高患者的依从性,并长时间维持血液或组织中的治疗水平。该研究将新型半合成聚合物和天然聚合物与众所周知的缓释剂进行了比较,以探究它们的作用。胃复安给药系统(GRDDS)是一种独特的技术,旨在通过避免首过效应来提高药物的生物利用度和吸收率。洛沙坦钾是一种血管紧张素 II 受体拮抗剂,其生物利用度为 32%,消除半衰期较短,因此适合口服控释。该研究利用天然和合成聚合物制备基质片剂、浓度、药物颗粒大小、添加剂和辅料来改变药物释放。对粉末混合物进行了压片前参数和压片后参数测试,体外溶出研究显示药物释放的溶出曲线良好。使用较高浓度和聚合物的制剂可持续释放药物 24 小时。傅立叶变换红外光谱法证实了药物与聚合物和其他辅料的相容性关键词:基质片剂、洛沙坦钾、流动特性、压缩前参数、压缩后参数、体外溶出度。